Use of tumor necrosis factor (TNF) as an adjuvant

Details Use of tumor necrosis factor (TNF) as an adjuvant Use of tumor necrosis factor (TNF) as an adjuvant

1987-01-21

1990-10-16

Draper, Garnette

Drug, bio-affecting and body treating compositions

Lymphokine

424 854, 514 2, 514 8, 514 12, 514 21, 514885, A61K 3702, A61K 3939

Patent

active

049633546

ABSTRACT:
Tumor necrosis factors, alone or together with cytokines such as IL-1 or INF-.gamma., are capable of serving as non-toxic vaccine adjuvants.

REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4770995 (1988-09-01), Rubin et al.
patent: 4791101 (1988-12-01), Adolf
patent: 4822605 (1989-04-01), Powell
patent: 4857314 (1989-08-01), O'Connor et al.
patent: 4863727 (1989-09-01), Zimmermon et al.
patent: 4879111 (1989-11-01), Chony
patent: 4894225 (1990-01-01), Zimmermon et al.
Philip et al., Nature, vol. 323, 1986, pp. 86-89.
Ruff et al., Inf. & Imm., 31(1) 1981, pp. 380-385.
Silherstein et al., PNAS 83, 1986, pp. 1055-1059.
Urban et al., PNAS 83, 1986, pp. 5233-5237.
Alexander et al., CA 107, 1987, #32744q.
Matsu et al., CA 107, 1987, #57005n.
Ghiara et al., J. Immunol. 139, 1987, pp. 3676-3679.

Affiliated with

Also associated with

Rating

Use of tumor necrosis factor (TNF) as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of tumor necrosis factor (TNF) as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tumor necrosis factor (TNF) as an adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-848774